Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule

European Journal of Cancer

Volumn 38, Issue 18, 2002, Pages 2388-2396

  Sessa, C ^a   Weigang Kohler K ^a   Pagani, O ^a   Greim, G ^b   Mor, O ^a,b,d   De Pas, T ^c   Burgess, M ^d   Weimer, I ^d   Johnson, R ^d  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b KLINIKUM NÜRNBERG   (Germany)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Analogue; Clinical pharmacology; Cryptophycin; New drugs; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOPHYCIN 52; CRYPTOPHYCIN DERIVATIVE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; HEART ARRHYTHMIA; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NEUROPATHY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; LACTAMS; LACTONES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 0036892740     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00489-6     Document Type: Article

References (15)

1. Bai R., Schwartz R.E.et al. Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res. 56:1996;4398-4406.
2. Berna M., Shugert R.et al. Determination of LY355703 in dog and mouse plasma by positive ion liquid chromatography/tandem mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom. 33:1998;138-143.
3. Cavaletti G., Bogliun G.et al. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol. 15:1997;199-206.
4. De Pas T.M., Mandala M.et al. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703. Obstet Gynecol. 95(6 Pt 2):2000;1030.
5. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biop Stat. 4:1994;147-164.
6. Mandema J., Verotta D.et al. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biop. 20:1992;5111-5128.
7. Panda D., DeLuca K.et al. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. PNAS U S A. 95:1998;9313-9318.
8. Panda D., Himes R.H.et al. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1. Biochem. 36:1997;12948-12953.
9. Postma T.J., Vermorken J.B.et al. Paclitaxel-induced neuropathy. Ann Oncol. 6:1995;489-494.
10. Schwartz R.E., Hirsch C.F.et al. Pharmaceuticals from cultured algae. J Ind Microbiol Biot. 5:1990;113-124.
11. Smith C.D., Zhang X.et al. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res. 54:1994;3779-3784.
12. Stevenson J.P., Gallagher M.et al. Phase I clinical and pharmacokinetic trial of cryptophycin-52 (LY355703) administered as an IV infusion on days 1, 4, 8, and 11 every 21 days. Proc Am Assoc Cancer Res. 42:2001;113a.
13. Wagner M.M., Paul D.C.et al. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemoth Pharm. 43:1999;115-125.
14. Handbook for Reporting Results of Cancer Treatment, (Vol. 48). 1979;World Health Organization, Geneva, Switzerland.
15. Worzalla J.F., Cao J.et al. LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts. Proc Natl Acad Can Res. 28:1997;225.